Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline
Workers | NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram …

Background Information is limited regarding the effectiveness of the two-dose messenger
RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in …

Background Workers critical to emergency response and continuity of essential services
during the COVID-19 pandemic are at a disproportionally high risk of SARS-CoV-2 infection. …

Introduction In a multi-center prospective cohort of essential workers, we assessed knowledge,
attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and …

In a cohort of essential workers in the United States previously infected with SARS-CoV-2,
risk factors for reinfection included being unvaccinated, infrequent mask use, time since first …

Background There are limited data on whether hybrid immunity differs by count and order of
immunity-conferring events (SARS-CoV-2 infection or COVID-19 vaccination). From a cohort …

Background We sought to evaluate the impact of changes in estimates of COVID‐19 vaccine
effectiveness on the incidence of laboratory‐confirmed infection among frontline workers at …

Background Data on the development of neutralizing antibodies (nAbs) against SARS-CoV-2
after SARS-CoV-2 infection and after vaccination with mRNA COVID-19 vaccines are …

Importance Bivalent mRNA COVID-19 vaccines were recommended in the US for children
and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 …

Per- and polyfluoroalkyl substances (PFAS) are ubiquitous throughout the United States.
Previous studies have shown PFAS exposure to be associated with a reduced immune …